Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
November 12th 2024Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.
Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma
November 11th 2024Panelists discuss how to tailor treatment strategies for a 67-year-old, BCMA-naïve woman with relapsed/refractory multiple myeloma, weighing the potential benefits of BCMA-targeted therapies against other available options in the context of her specific clinical presentation.
Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective
November 11th 2024Panelists discuss how a patient experienced care coordination during treatment at Memorial Sloan Kettering (MSK), detailing the health care professionals involved, the integration of services such as wound care and integrative medicine, and the positive impact of a team-based approach on her treatment experience and confidence in her care.
Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach
November 11th 2024Panelists discuss how effective care coordination at Memorial Sloan Kettering (MSK) involves a multidisciplinary team of health care professionals working collaboratively to optimize the patient’s journey from diagnosis through treatment and follow-up, highlighting the essential role of nurse practitioners in this process.
Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma
November 11th 2024Panelists discuss how to approach treatment decisions for a 68-year-old woman with triple-class exposed relapsed/refractory multiple myeloma, considering factors such as prior therapies, disease characteristics, and emerging treatment options to optimize her care.
Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas
November 11th 2024Panelists discuss how they tailor treatment strategies for oligodendrogliomas and Grade 2 gliomas based on key clinical and molecular markers, with particular attention to insights from the CODEL trial and RTOG 9802 study.
An Overview of HER2 Alterations in NSCLC and Implications for Treatment
November 8th 2024Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.
Areas for Improvement in Real-World GPRC5D-Targeted Therapy Application
November 8th 2024Panelists discuss how key areas for improvement in the application of GPRC5D-targeted therapies in real-world settings include optimizing patient selection, addressing logistical challenges, and enhancing adverse event management.
Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma
November 8th 2024Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
Long-Term CARTITUDE 4: Rate of MRD Negativity
November 8th 2024Panelists discuss how data from the long-term CARTITUDE-4 update reveal a notable rate of minimal residual disease (MRD) negativity with ciltacabtagene autoleucel, emphasizing its potential to enhance long-term outcomes in patients with lenalidomide-refractory multiple myeloma.
42nd Annual CFS Preview for Integrative Care: The Show and After Show
November 7th 2024CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.
Treatment Paradigm for Early-Stage Pancreatic Cancer Diagnosis
November 7th 2024With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment paradigm for early-stage pancreatic cancer, focusing on diagnostic strategies, surgical options, and adjuvant therapies to improve patient outcomes.
Treatment Considerations for Resectable Pancreatic Cancer
November 7th 2024With Eileen O’Reilly, MD, the Oncology Brothers discuss treatment considerations for resectable pancreatic cancer, including criteria for surgical resection, the role of adjuvant therapies, and strategies to optimize patient outcomes post surgery.
Treatment Paradigm for Metastatic Pancreatic Cancer
November 7th 2024With Eileen O’Reilly, MD, the Oncology Brothers discuss the treatment paradigm for metastatic pancreatic cancer, covering systemic therapies, the role of targeted treatments, and strategies for managing disease progression and improving quality of life.
Treatment Considerations for Disease Progression
November 7th 2024With Eileen O’Reilly, MD, the Oncology Brothers discuss treatment considerations for disease progression in pancreatic cancer, focusing on the management of refractory disease, shifting therapeutic strategies, and optimizing patient care in advanced stages.